Safety of a peanut oral immunotherapy protocol in children with peanut allergy

Abstract

Background: Oral immunotherapy (OIT) offers a promising therapeutic option for peanut allergy. Given that during OIT an allergic patient ingests an allergen that could potentially cause a serious reaction, the safety of OIT is of particular concern.

Objective: The purpose of this study was to examine safety during the initial escalation day, buildup phase, and home dosing phase in subjects enrolled in a peanut OIT study.

Methods: Skin, upper respiratory tract, chest, and abdominal symptoms were recorded with initial escalation day and buildup phase dosings. Subjects also maintained daily diaries detailing symptoms after each home dosing. A statistical analysis of these data was performed.

Results: Twenty of 28 patients completed all phases of the study. During the initial escalation day, upper respiratory tract (79%) and abdominal (68%) symptoms were the most likely symptoms experienced. The risk of mild wheezing during the initial escalation day was 18%. The probability of having any symptoms after a buildup phase dose was 46%, with a risk of 29% for upper respiratory tract symptoms and 24% for skin symptoms. The risk of reaction with any home dose was 3.5%. Upper respiratory tract (1.2%) and skin (1.1%) symptoms were the most likely after home doses. Treatment was given with 0.7% of home doses. Two subjects received epinephrine after 1 home dose each.

Conclusions: Subjects were more likely to have significant allergic symptoms during the initial escalation day when they were in a closely monitored setting than during other phases of the study. Allergic reactions with home doses were rare.

Figures

Figure 1

Estimated Risk of Specific Symptoms during the Initial Escalation Day. Symptoms were recorded during the initial escalation day in four categories: upper respiratory, skin, abdominal, and chest.

Figure 2

Estimated Risk of Specific Symptoms During the Build-up Phase. Symptoms were recorded during the buildup phase in four categories: upper respiratory, skin, abdominal, and chest.

Figure 3

Estimated Risk of Specific Symptoms During the Home Dosing Phase. Symptoms were recorded during the home dosing phase in four categories: upper respiratory, skin, abdominal, and chest.